Silence Therapeutics
SLN
26 hedge funds and large institutions have $218M invested in Silence Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
18% more funds holding
Funds holding: 22 → 26 (+4)
2.05% more ownership
Funds ownership: 11.52% → 13.57% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
12% less capital invested
Capital invested by funds: $247M → $218M (-$28.4M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAME
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$31.1M |
| 2 |
Goldman Sachs
New York
|
+$4.1M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$3.18M |
| 4 |
ACM
Altium Capital Management
New York
|
+$2.17M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$298K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$21.2M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$2.08M |
| 3 |
CF
Cantor Fitzgerald
New York
|
-$1.61M |
| 4 |
Morgan Stanley
New York
|
-$303K |
| 5 |
JP Morgan Chase
New York
|
-$157K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FM
26
Frazier Management
Seattle,
Washington
| – | -$21.2M | -886,173 | Closed |
|
|
27
JP Morgan Chase
New York
| – | -$157K | -6,730 | Closed |
|
|
CSS
28
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$4K | -184 | Closed |
|
SLN Hedge Fund Activity: Q1 2022 in Review
26 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q1 2022, worth a combined $218M — down 12% from $247M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SLN positions and 3 closed out — a net gain of 4 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Lombard Odier Asset Management (Europe), opening a new position worth an estimated $31.1M. The largest seller was Frazier Management, exiting entirely with an estimated $21.2M sold.
- 26 institutional investors held Silence Therapeutics (SLN) as of Q1 2022, up from 22 in Q4 2021.
- Funds reported $218M of Silence Therapeutics stock for Q1 2022, down 12% quarter-over-quarter.
- 7 funds opened new Silence Therapeutics positions in Q1 2022 and 3 closed out, a net change of +4 holders.
- The largest Silence Therapeutics buyer in Q1 2022 was Lombard Odier Asset Management (Europe), an estimated $31.1M added.
- The largest Silence Therapeutics seller in Q1 2022 was Frazier Management, an estimated $21.2M sold.
Based on aggregated 13F filings for Q1 2022.